Additionally, luteolin epigenetically decreases the CpG methylation of the Nrf-2 promoter by inhibiting DNA methyltransferase (DNMT) and histone deacetylase (HDAC) expression resulting in Nrf-2 activation in colon cancer cells [68]. Here, NFE2L2 is linked to malignant colon neoplasm.